What You Should Know
- Eko Health has appointed Steven R. Steinhubl, MD, a prominent cardiologist and digital medicine pioneer, as its Chief Medical Officer (CMO) and executive leadership team member.
- Dr. Steinhubl will oversee Eko’s clinical strategy, research initiatives, and scientific collaborations to accelerate the global adoption of AI-enabled cardiac detection.
- He currently serves as the Vincent P. Reilly Professor of Biomedical Engineering at Purdue University and is a member of the Regenstrief Center for Healthcare Engineering.
- The appointment follows a landmark year for Eko, including CMS national payment for its SENSORA® platform and a major publication in The Lancet.
- Eko Health’s FDA-cleared platform has sold more than 700,000 devices worldwide, aiding in the early detection of heart and lung disease.
Early detection of cardiovascular disease remains a global challenge, with over 60% of cases often going undiagnosed. Eko Health is bridging this gap by embedding artificial intelligence into the clinical tools providers use daily—the stethoscope and ECG. By naming Dr. Steven Steinhubl as Chief Medical Officer, Eko is doubling down on its mission to translate high-fidelity physiological data into seamless, point-of-care analytics that do not disrupt established clinical workflows.
Dr. Steinhubl’s multidisciplinary background in engineering, physiology, and medicine uniquely qualifies him to advance Eko’s clinical evidence base. His career has been dedicated to using wearables and AI to address health inequities and transition care from late-stage hospitalizations to proactive, outpatient management.
Accelerating Clinical Evidence and Global Reach
Dr. Steinhubl joins Eko Health during a period of significant clinical and commercial expansion. Over the past year, the company has achieved several critical milestones:
- Landmark Clinical Validation: The TRICORDER study, published in The Lancet in early 2026, demonstrated that AI-assisted stethoscope exams increased detection of heart failure by 2.3x and atrial fibrillation by 3.5x compared to standard practice.
- Reimbursement Success: In July 2025, CMS finalized national payment for Eko’s SENSORA® platform under the Outpatient Prospective Payment System (OPPS), assigning a reimbursement rate of $128.90 per use.
- Global Expansion: Eko launched its AI-powered platform in the United Kingdom in April 2025 and expanded into Canada following Health Canada clearance of the CORE 500™ Digital Stethoscope.
- Rural Healthcare Support: Eko partnered with Wayne General Hospital to deploy AI screening tools specifically aimed at improving cardiovascular care in rural, underserved communities.
Dr. Steinhubl’s leadership is expected to further strengthen these clinical partnerships, ensuring that Eko’s technology continues to drive meaningful outcomes for the 1.5 million patients already being served by Eko-enabled clinicians globally.
